324 related articles for article (PubMed ID: 9511177)
1. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
2. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
3. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population.
Niewinski P; Orzechowska-Juzwenko K; Hurkacz M; Rzemislawska Z; Jaźwinska-Tarnawska E; Milejski P; Forkasiewicz Z
Eur J Clin Pharmacol; 2002 Nov; 58(8):533-5. PubMed ID: 12536989
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
10. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
Raimundo S; Fischer J; Eichelbaum M; Griese EU; Schwab M; Zanger UM
Pharmacogenetics; 2000 Oct; 10(7):577-81. PubMed ID: 11037799
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
14. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.
Isaza CA; Henao J; López AM; Cacabelos R
Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):695-705. PubMed ID: 11294012
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
16. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
[TBL] [Abstract][Full Text] [Related]
17. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
18. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
Rau T; Heide R; Bergmann K; Wuttke H; Werner U; Feifel N; Eschenhagen T
Pharmacogenetics; 2002 Aug; 12(6):465-72. PubMed ID: 12172215
[TBL] [Abstract][Full Text] [Related]
19. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction.
Stüven T; Griese EU; Kroemer HK; Eichelbaum M; Zanger UM
Pharmacogenetics; 1996 Oct; 6(5):417-21. PubMed ID: 8946473
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
